Severe macular complications in glaucoma: high-resolution multimodal imaging characteristics and review of the literature.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
14 Jul 2023
Historique:
received: 07 08 2022
accepted: 03 07 2023
medline: 17 7 2023
pubmed: 15 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

To describe imaging characteristics of severe macular complications occurring in glaucoma and discuss available treatments. Retrospective case series of glaucomatous patients with macular retinoschisis (MR) and/or serous retinal detachment (SRD). Patients underwent a complete ophthalmological examination and multimodal imaging including retinography, SD-OCT, fluorescein and indocyanine green angiography (FA & ICGA) and adaptive optics (AO). Ten eyes (8 patients) were included. Initial BCVA was 1.04 ± 1.12 logMAR and IOP was 24.0 ± 9.3mmHg. All eyes presented with MR while SRD was present in 5 eyes (5 patients), with a central macular thickness of 573 ± 152 μm. FA and ICGA allowed to exclude leakage in all cases. A focal lamina cribrosa defect (LCD) was found in four eyes (4 patients) using OCT, with AO providing en-face visualization of the defect in one eye. Outer retinal hole was present in 3 eyes (3 patients). No visual improvement or resolution of the macular retinoschisis was observed in eyes with medical or surgical IOP control (N = 9). Vitrectomy with internal membrane limiting peeling and gas tamponade was performed in one eye with good visual results. Multimodal high-resolution imaging is essential to diagnose severe macular complications associated with advanced glaucoma.

Identifiants

pubmed: 37452284
doi: 10.1186/s12886-023-03068-z
pii: 10.1186/s12886-023-03068-z
pmc: PMC10347769
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

318

Informations de copyright

© 2023. The Author(s).

Références

Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1255-8
pubmed: 21455774
Eye (Lond). 2013 Dec;27(12):1359-67
pubmed: 24037231
Prog Retin Eye Res. 2012 May;31(3):195-212
pubmed: 22245536
Jpn J Ophthalmol. 2014 Sep;58(5):435-42
pubmed: 24931650
Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):281-288
pubmed: 29164327
JAMA Ophthalmol. 2013 Mar;131(3):314-20
pubmed: 23370812
Acta Ophthalmol. 2015 Jun;93(4):e317-8
pubmed: 25384451
Case Rep Ophthalmol Med. 2015;2015:432782
pubmed: 26356828
Am J Ophthalmol. 2007 Jul;144(1):70-74
pubmed: 17493573
JAMA Ophthalmol. 2016 Jan;134(1):108-10
pubmed: 26540576
Clin Ophthalmol. 2020 Jun 16;14:1601-1608
pubmed: 32606575
BMJ Case Rep. 2015 Jul 21;2015:
pubmed: 26199301
Arch Ophthalmol. 2004 Dec;122(12):1793-800
pubmed: 15596582
Retina. 1992;12(2):127-33
pubmed: 1439243
J Glaucoma. 2016 Mar;25(3):258-62
pubmed: 25265005
Graefes Arch Clin Exp Ophthalmol. 2015 Sep;253(9):1447-56
pubmed: 25341955
Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):107-10
pubmed: 25559522
Ophthalmology. 2016 Oct;123(10):2066-76
pubmed: 27506483
Can J Ophthalmol. 2014 Apr;49(2):e56-9
pubmed: 24767243
Br J Ophthalmol. 2016 Apr;100(4):478-83
pubmed: 26294101
Retina. 2015 Oct;35(10):2011-7
pubmed: 25923958
Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4798-807
pubmed: 23778878
Am J Ophthalmol. 2014 Sep;158(3):423-35
pubmed: 24932988
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2818-2827
pubmed: 29860466
Arch Ophthalmol. 1992 Dec;110(12):1786-92
pubmed: 1463423
Eye (Lond). 2017 Mar;31(3):499-502
pubmed: 27834967
Am J Ophthalmol. 1969 Jun;67(6):821-41
pubmed: 5795739
J Glaucoma. 2017 Jun;26(6):e180-e186
pubmed: 28221332
Arch Ophthalmol. 2012 May;130(5):552-9
pubmed: 22232364
Ophthalmic Surg Lasers Imaging Retina. 2014 Nov-Dec;45(6):598-600
pubmed: 25423643
Arch Ophthalmol. 2004 Mar;122(3):409-11
pubmed: 15006866
PLoS One. 2014 Feb 28;9(2):e90129
pubmed: 24587238
J Fr Ophtalmol. 2016 Mar;39(3):265-71
pubmed: 26987895
Ophthalmic Genet. 2019 Jun;40(3):207-212
pubmed: 31149861
Eur J Ophthalmol. 2021 Jul;31(4):2160-2164
pubmed: 33135502

Auteurs

Hugo Lama (H)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France.

Michel Pâques (M)

Department of Ophthalmology, Quinze-Vingts National Eye Hospital, IHU Foresight, Paris, France.

Emmanuelle Brasnu (E)

Department of Ophthalmology, Quinze-Vingts National Eye Hospital, IHU Foresight, Paris, France.

Jade Vu (J)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France.
Ophtalmopôle Cochin, APHP, Paris, France.

Céline Chaumette (C)

Department of Ophthalmology, Quinze-Vingts National Eye Hospital, IHU Foresight, Paris, France.

Bénédicte Dupas (B)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France.

Christine Fardeau (C)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France.
Department of Ophthalmology, Pitié Salpétrière Hospital, APHP, Paris, France.

Ismaël Chehaibou (I)

Ophtalmopôle Cochin, APHP, Paris, France.

Jean-François Rouland (JF)

Department of Ophthalmology, Hôpital Claude Huriez, CHRU, Lille, France.

Guillaume Besombes (G)

Department of Ophthalmology, Hôpital Claude Huriez, CHRU, Lille, France.

Marc Labetoulle (M)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France.

Antoine Labbé (A)

Department of Ophthalmology, Quinze-Vingts National Eye Hospital, IHU Foresight, Paris, France.

Antoine Rousseau (A)

Department of Ophthalmology, Assistance Publique - Hôpitaux de Paris - Université Paris Saclay, 78, rue du Général Leclerc, Le Kremlin Bicêtre, 94275, France. antoine.rousseau@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH